Related Experiment Video
Updated: Mar 27, 2026
08:19
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
18.8K
Solid Lipid Nanoparticles for Image-Guided Therapy of Atherosclerosis
Khalid Oumzil1,2, Michael A Ramin1,2, Cyril Lorenzato3
1University of Bordeaux, ARNA laboratory , F-33000 Bordeaux, France.
Bioconjugate Chemistry
|January 12, 2016
Summary
Researchers developed novel solid lipid nanoparticles (SLNs) for atherosclerosis treatment. These nanoparticles combine iron oxide for imaging and prostacyclin to prevent platelet aggregation, offering improved MRI contrast for image-guided therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiovascular Research
Background:
- Atherosclerosis poses a significant public health challenge requiring innovative treatment strategies.
- Magnetic Resonance Imaging (MRI) is being explored for image-guided therapeutic interventions.
- Current nanotechnology applications in atherosclerosis are still emerging.
Purpose of the Study:
- To develop novel solid lipid nanoparticles (SLNs) for atherosclerosis management.
- To integrate MRI contrast agents and therapeutic agents within SLNs.
- To evaluate the potential of these SLNs for image-guided therapy.
Main Methods:
- Synthesis of SLNs using nucleoside-lipids.
- Loading SLNs with iron oxide particles and prostacyclin (PGI2).
- Assessment of SLN stability and relaxivity properties.
Main Results:
- Stable SLNs were successfully synthesized using nucleoside-lipids.
- The SLNs effectively encapsulated prostacyclin (PGI2), inhibiting platelet aggregation.
- The developed SLNs demonstrated superior MRI relaxivity compared to Feridex.
Conclusions:
- Nucleoside-lipid-based SLNs are a promising platform for image-guided atherosclerosis therapy.
- These SLNs offer enhanced MRI contrast for better visualization.
- The dual functionality of imaging and therapeutic delivery holds potential for improved patient outcomes.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:26Atherosclerosis III: Management
578
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
01:30Atherosclerosis I: Introduction
1.9K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.9K